Aker BioMarine ASA (OSL:AKBM)
Norway · Delayed Price · Currency is NOK 122.40
-1.80 (-1.45%)
Aug 24, 2026, 4:25 PM CET
Aker BioMarine ASA Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 227.2 | 218.1 | 199 | 196.3 | 277.2 | 262.1 |
Revenue Growth | 9.55% | 9.60% | 1.38% | -29.18% | 5.76% | -9.18% |
Gross Profit Gross Profit Growth | 102.3 | 97.8 | 78.4 | 72.5 | 114.8 | 88.1 |
Operating Income Operating Income Growth | 14.7 | 12.8 | -4 | -10.3 | 16.3 | -6.9 |
Net Income Net Income Growth | -13.3 | -22.8 | 182.6 | -9 | 10 | -8 |
Earnings Per Share EPS Growth | -0.11 | -0.26 | 2.08 | -0.10 | 0.11 | -0.09 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Other/Eliminations Other/Eliminations Growth | -15.8 | -16.7 | -18.1 | -20.7 | -14.3 | -17.9 |
Human Health Ingredients Human Health Ingredients Growth | 128.8 | 118.2 | 97.9 | 83.7 | - | - |
Consumer Health Products Consumer Health Products Growth | 106.3 | 108.5 | 109.4 | 122.2 | - | - |
Emerging Businesses Emerging Businesses Growth | - | 8.3 | 9.7 | 11.1 | - | - |
Total Total Growth | 227.6 | 218.3 | 198.9 | 196.3 | 277.2 | 262.1 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 19.7 | 16.9 | 15 | 27.5 | 22.3 | 11.1 |
Total Debt Total Debt Growth | 204.8 | 182.2 | 147.5 | 393 | 381.2 | 324.8 |
Net Cash (Debt) Net Cash Growth | -185.1 | -165.3 | -132.5 | -365.5 | -358.9 | -313.7 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -1.50 | -1.88 | -1.51 | -4.17 | -4.10 | -3.58 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -6 | 4.2 | 12.2 | 47.4 | 15.1 | 2.6 |
Capital Expenditures CapEx Growth | -7.9 | -6.3 | -17.4 | -45.9 | -40.5 | -78.7 |
Free Cash Flow Free Cash Flow Growth | -13.9 | -2.1 | -5.2 | 1.5 | -25.4 | -76.1 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 45.03% | 44.84% | 39.40% | 36.93% | 41.41% | 33.61% |
Operating Margin | 6.47% | 5.87% | -2.01% | -5.25% | 5.88% | -2.63% |
Pretax Margin | -4.18% | -1.28% | -6.08% | -16.45% | 4.40% | -2.82% |
Profit Margin | -5.85% | -10.45% | 91.76% | -4.58% | 3.61% | -3.05% |
FCF Margin | -6.12% | -0.96% | -2.61% | 0.76% | -9.16% | -29.04% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 25, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 2.84 | - | 33.85 | - |
Forward PE | 36.56 | 39.34 | 179.33 | 80.58 | 30.13 | 192.08 |
P/FCF Ratio | - | - | - | 265.14 | - | - |
PS Ratio | 4.77 | 3.94 | 2.60 | 2.03 | 1.22 | 2.06 |